News

Therabron Therapeutics’ lead biopharmaceutical product candidate is a proprietary preparation of recombinant human CC10 protein which has potential clinical applications, based on its potent anti-inflammatory properties, in a

The deal gives AbbVie rights to Stemcentrx’s experimental treatment for a form of lung cancer and other experimental drugs. Stemcentrx’s lead late-stage asset rovalpituzumab tesirine (Rova-T) is presently

The phase IIb trial is a global multicentric study, randomized versus placebo, started in October last year in Lupus. It intends to assess the biological and clinical efficacy

Medivation develops and commercializes medically innovative therapies to treat severe diseases for which there are limited treatment options. The company has one marketed prostate cancer therapy, Xtandi, and

Lonsurf is indicated to treat adult patients with mCRC who have earlier been treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based

The US Food and Drug Administration (FDA) has cleared Cumberland’s investigational new drug application (IND) for Phase II clinical program for Vasculan in patients with systemic sclerosis. "Cumberland

X-Chem met this milestone under a partnership established with Alexion in December 2014. Under the terms of the agreement, Alexion obtains exclusive worldwide rights to develop and commercialize

IBC Generium chief business officer Daniil Talyanskiy said: "Our scientific staff at IBC Generium developed GNR-047, an IgG-based anti-CD3 / anti-CD19 bispecific antibody for the treatment of oncohematological

Based on this review, the company intends to initiate the first of two Phase 3 clinical trials during the third quarter of 2016. The FDA has stated that